News
Thu, 05 Dec 2024 08:00:00 -0500
Thu, 05 Dec 2024 08:00:00 -0500
PLAINSBORO, N.J., Dec. 05, 2024 -- Novo Nordisk today announced plans to reduce the US list prices of two insulin products by more than 70% to better meet the needs of people living with diabetes.
The list prices of vials and pre-filled pens of insulin aspart (rapid-acting) and basal insulin (long-acting), specifically Tresiba® and Fiasp®, will be reduced in the US starting January 1, 2026. Those new list prices, also referred to as wholesale acquisition costs (WAC), will be:
|
Tresiba® |
U-100 Vial |
U-100 Device |
U-200 Device |
|
|
|
|
|
|
Current WAC/pkg |
$338.95 |
$508.43 |
$610.11 |
|
New WAC/pkg |
$94.29 |
$141.43 |
$169.71 |
|
Fiasp® |
Vial |
FlexTouch® |
PenFill® |
PumpCart® |
|
|
|
|
|
|
|
Current WAC/pkg |
$289.36 |
$558.83 |
$537.47 |
$286.65 |
|
New WAC/pkg |
$72.34 |
$139.71 |
$134.37 |
$71.66 |
The list prices of Fiasp® will be reduced by 75%, matching the price of NovoLog®. Additionally, the list prices of Tresiba® will be reduced by 72.2%, making it 20% lower than its unbranded biologic equivalent, insulin degludec, thereby rendering the latter redundant. As such, Novo Nordisk Pharma, Inc. will discontinue the unbranded biologic versions below by December 31, 2025.
Novo Nordisk is making healthcare professionals, wholesalers and payers aware of the discontinuations more than 12 months in advance, so they can enable smooth transitions to other options. Patients should speak with their healthcare professional about their treatment options to determine the best course of action.
Novo Nordisk remains steadfast in its commitment to patients and recognizes that accessing medicines is a real challenge for people living with diabetes. To help as many people as possible, Novo Nordisk continues to offer a variety of insulin affordability options for people with or without insurance through NovoCare. In 2023 alone, NovoCare helped nearly 1.5 million people living with diabetes. Patients can visit NovoCare.com for more information.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With U.S headquarters in New Jersey and commercial, production, and research facilities in seven states plus Washington DC, Novo Nordisk employs approximately 8,000 people throughout the country. For more information, visit novonordisk-us.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
|
Media: |
Investor Relations: |
|
Liz Skrbkova (US) |
Frederik Taylor Pitter (US) |
_______________________